Clinical trials: Obesity & Overweight
Obesity, Overweight
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
- Trial name
- NCT06683508
- Testing
- LY3549492
- Where
- 49 sites in United States
- Volunteers
- 288 people
- Sponsor
- Eli Lilly and Company
Obesity Associated With Defects in Leptin-melanocortin Pathway
Open-Label Extension Study of Setmelanotide
This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous…
- Trial name
- NCT06596135
- Testing
- Setmelanotide
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
- Trial name
- NCT02518685
- Testing
- TransPyloric Shuttle, Lifestyle Counseling
- Where
- 9 sites in United States
- Volunteers
- 302 people
- Sponsor
- BaroNova, Inc.
Obesity, Mild
Safety & Effectiveness of TENS Weight Management Compared to a Sham
This is a multicenter, randomized, blinded, parallel group, controlled study intended to evaluate the safety and effectiveness of treating overweight and Class 1 obese patients with the Elira System (TENS active treatment)…
- Trial name
- NCT05675384
- Testing
- TENS Active Treatment
- Where
- 6 sites in United States
- Volunteers
- 395 people
- Sponsor
- Elira, Inc.
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Obesity
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar…
- Trial name
- STEP 10 (NCT05040971)
- Testing
- Semaglutide 2.4 mg
- Where
- 43 sites in Canada, Denmark and 3 more
- Volunteers
- 207 people
- Sponsor
- Novo Nordisk A/S
Obese Adults
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without…
- Trial name
- NCT07846033
- Testing
- SC VK3019
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Viking Therapeutics, Inc.
Overweight or Obesity; Type 2 Diabetes
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.
- Trial name
- NCT06435676
- Testing
- HRS9531
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
Study to Evaluate Novel Gastric Space Occupying Device
This will be an observational, prospective, non-randomized, pilot study to gain initial device experience on a novel space-occupying device in persons who are overweight or obese. No formal hypothesis testing will be conducted.
- Trial name
- NCT01288456
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Obalon Therapeutics, Inc.
Obesity
Efficacy and Safety of THR-4109 in Obese Subjects
The purpose of this study is to evaluate the safety and effect of THR-4109 on weight loss in obese subjects over a 24-week treatment period.
- Trial name
- NCT00485017
- Testing
- THR-4109
- Where
- 20 sites in Russia, Sweden
- Volunteers
- 220 people
- Sponsor
- Theracos
Obesity, Adiposity
HybridAPC for Gastric Mucosal Ablation in Obese Patients.
This study is intended to investigate safety and feasibility of a new weight loss technique called Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
- Trial name
- NCT05587491
- Testing
- Hybrid Argonplasma coagulation (HAPC)
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Erbe Elektromedizin GmbH
Obesity
A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects
Safety and effectiveness of the BIB® System in conjunction with a behavior modification program compared to the behavior modification program alone for weight loss in obese subjects.
- Trial name
- NCT00730327
- Testing
- BioEnterics® Intragastric Balloon, Behavioral modification
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Apollo Endosurgery, Inc.
Obesity
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities.
- Trial name
- NCT00386061
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 1,507 people
- Sponsor
- Sanofi
Overweight, Obesity
A Study of LY3457263 in Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants.
- Trial name
- NCT05582096
- Testing
- LY3457263, Tirzepatide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet.
- Trial name
- NCT04086797
- Testing
- IQP-AE-103
- Where
- Germany
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Obesity
One-Year Study of S1B-509 vs Placebo for Weight Loss
This is a study to test whether S1B-509 given orally daily helps people with overweight or obesity to lose more weight than with placebo over a year.
- Trial name
- NCT06517797
- Testing
- S1B-509 low dose, S1B-509 High Dose
- Volunteers
- 210 people
- Sponsor
- S1 Biopharma, Inc.
Satiety, Appetite
A Study of NatureU Burn on Satiety in Healthy Adults
This single-center, single-blind, non-randomized crossover exploratory study evaluated the short-term effects of NatureU Burn on postprandial satiety in healthy adults.
- Conditions
- Satiety, Appetite, Food Intake, Fat Disorder
- Trial name
- NUBURN (NCT07597382)
- Testing
- Glucose Reference Food, NatureU Burn Plus Glucose
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- OmniSolutions Laboratory Holdings Limited
Healthy Overweight Obese
Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters
The purpose of this study is to determine the safety and tolerability of Gelesis200.
- Trial name
- STAGE (NCT02652962)
- Testing
- Gelesis200
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
Overweight and Obesity
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
- Trial name
- NCT07313761
- Testing
- Maridebart Cafraglutide
- Where
- 4 sites in United States
- Volunteers
- 349 people
- Sponsor
- Amgen
Overweight, Obese
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
The purpose of this study is to evaluate the multiple dose safety and tolerability of RM-493 (setmelanotide) as well as pharmacokinetic (PK) and pharmacodynamic (PD; weight loss) profile, in healthy obese patients for 2 to 4…
- Trial name
- NCT02431442
- Testing
- RM-493
- Volunteers
- 57 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.